Insider Selling: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Sells 11,447 Shares of Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) Director Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Tuesday, April 16th. The stock was sold at an average price of $7.66, for a total value of $87,684.02. Following the transaction, the director now owns 7,229,861 shares in the company, valued at approximately $55,380,735.26. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Blake Borgeson also recently made the following trade(s):

• On Tuesday, April 2nd, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $8.82, for a total value of $100,962.54.
• On Tuesday, March 19th, Blake Borgeson sold 20,054 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $10.79, for a total value of $216,382.66.
• On Tuesday, March 5th, Blake Borgeson sold 20,054 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $12.06, for a total value of $241,851.24.
• On Tuesday, February 20th, Blake Borgeson sold 20,054 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $12.32, for a total value of $247,065.28.
• On Tuesday, February 6th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $9.30, for a total value of $106,457.10.
• On Tuesday, January 23rd, Blake Borgeson sold 20,054 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $10.58, for a total value of $212,171.32.

Recursion Pharmaceuticals Trading Down 0.9 %

RXRX traded down $0.07 on Thursday, hitting $7.40. 2,860,086 shares of the company were exchanged, compared to its average volume of 6,626,345. Recursion Pharmaceuticals, Inc. has a twelve month low of $4.54 and a twelve month high of $16.75. The company has a market cap of $1.74 billion, a price-to-earnings ratio of -4.77 and a beta of 0.76. The firm has a 50-day moving average price of $10.84 and a two-hundred day moving average price of $9.10.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last announced its quarterly earnings results on Tuesday, February 27th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.46) by $0.06. The company had revenue of $10.89 million during the quarter, compared to the consensus estimate of $12.37 million. Recursion Pharmaceuticals had a negative return on equity of 72.88% and a negative net margin of 735.99%. Equities analysts expect that Recursion Pharmaceuticals, Inc. will post -1.63 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on RXRX. KeyCorp lifted their price objective on Recursion Pharmaceuticals from $15.00 to $16.00 and gave the company an "overweight" rating in a research note on Monday, March 4th. TD Cowen initiated coverage on Recursion Pharmaceuticals in a research note on Friday, January 26th. They set a "market perform" rating for the company. Finally, Needham & Company LLC reissued a "buy" rating and set a $17.00 target price on shares of Recursion Pharmaceuticals in a research note on Tuesday, April 9th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, Recursion Pharmaceuticals currently has an average rating of "Hold" and an average price target of $12.75.

Institutional Investors Weigh In On Recursion Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of RXRX. ARK Investment Management LLC grew its holdings in shares of Recursion Pharmaceuticals by 200.4% in the 4th quarter. ARK Investment Management LLC now owns 20,654,287 shares of the company's stock worth $203,651,000 after acquiring an additional 13,777,689 shares during the period. Mubadala Investment Co PJSC acquired a new stake in shares of Recursion Pharmaceuticals in the 4th quarter worth approximately $128,041,000. Nvidia Corp acquired a new stake in shares of Recursion Pharmaceuticals in the 4th quarter worth approximately $75,985,000. FMR LLC grew its holdings in shares of Recursion Pharmaceuticals by 134.4% in the 3rd quarter. FMR LLC now owns 10,689,532 shares of the company's stock worth $81,775,000 after acquiring an additional 6,129,935 shares during the period. Finally, Sumitomo Mitsui Trust Holdings Inc. grew its holdings in shares of Recursion Pharmaceuticals by 161.2% in the 4th quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 9,203,780 shares of the company's stock worth $90,749,000 after acquiring an additional 5,680,656 shares during the period. Institutional investors and hedge funds own 89.06% of the company's stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.